WTG
EW icon

West Tower Group’s Edwards Lifesciences EW Stock Holding History

West Tower Group’s Portfolio EW Stock Details EW Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-1,172
Closed -$81.2K – 595
2023
Q3 		$81.2K Buy
1,172
+1,078
+1,147% +$86.6K 0.04% 123
2023
Q2 		$8.87K Buy
+94
New +$8.17K 0.01% 446

Other funds holding EW

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return
Brown Advisory
Brown Advisory Baltimore, Maryland $64.6B AUM 18.98% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $1T AUM

West Tower Group's EW Position: Q4 2023 in Review

West Tower Group sold out of Edwards Lifesciences (EW) in Q4 2023, closing a stake of 1,172 shares — an estimated $81.2K sold.

West Tower Group first reported a position in EW in Q2 2023 and held it in 2 quarters. The position peaked at $81.2K in Q3 2023. 1,245 funds tracked by Wall St. Rank hold EW as of Q4 2023.

  • West Tower Group reported no remaining Edwards Lifesciences position as of Q4 2023 after selling out during the quarter.
  • West Tower Group sold 1,172 Edwards Lifesciences shares in Q4 2023, an estimated $81.2K.
  • West Tower Group first reported a position in Edwards Lifesciences in Q2 2023 and held it in 2 quarters.
  • West Tower Group's Edwards Lifesciences position peaked at $81.2K in Q3 2023.
  • 1,245 funds tracked by Wall St. Rank held Edwards Lifesciences as of Q4 2023.

Based on West Tower Group's 13F filing for Q4 2023, filed 14 Feb 2024.